Close Menu

NEW YORK (GenomeWeb News) – Arcxis Biotechnologies said today that it has inked a partnership with In-Q-Tel to accelerate development and commercialization of the firm's nucleic acid sample preparation platform and diagnostic consumable product line.

Arcxis said the investment from In-Q-Tel is linked to the firm's recent round of private financing led by Claremont Creek Ventures, Kaiser Permanente Ventures, and Alafi Capital. The firm has not disclosed how much money it raised in that series B round, and it is not disclosing the amount of funding it has received from In-Q-Tel.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.